Open in Screener

COGT

Cogent Biosciences Inc

Jul 23 • 12:32PM ET

12.69

Dollar change +0.24
Percentage change 1.94	%

Healthcare • Biotechnology • USA • NASD

Peers: BLUE VRTX BEAM CRSP BPMC NTLA GILD EDIT ALLO FATE

| Held by: IWM VTI XBI VXF IWO SCHA IBB VTWO IWC FESM

Index	RUT	P/E	-	EPS (ttm)	-2.38	Insider Own	23.05%	Shs Outstand	163.81M	Perf Week	7.01%
Market Cap	2.08B	Forward P/E	-	EPS next Y	-1.92	Insider Trans	7.94%	Shs Float	126.05M	Perf Month	74.82%
Enterprise Value	1.96B	PEG	-	EPS next Q	-0.59	Inst Own	71.14%	Short Float	9.84%	Perf Quarter	192.44%
Income	-256.98M	P/S	-	EPS this Y	11.15%	Inst Trans	27.92%	Short Ratio	4.49	Perf Half Y	54.78%
Sales	0.00M	P/B	13.04	EPS next Y	11.97%	ROA	-70.93%	Short Interest	12.40M	Perf YTD	62.71%
Book/sh	0.97	P/C	8.46	EPS next 5Y	30.24%	ROE	-84.04%	52W High	12.97 -2.15%	Perf Year	47.41%
Cash/sh	1.50	P/FCF	-	EPS past 3/5Y	-9.70% 10.02%	ROIC	-109.60%	52W Low	3.72 241.17%	Perf 3Y	19.73%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.87% 7.30%	Perf 5Y	14.13%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	4.02%	Oper. Margin	-	ATR (14)	0.71	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.13	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	87.99	Recom	1.50
Dividend Gr. 3/5Y	- -	Current Ratio	5.13	EPS Q/Q	14.72%	SMA20	27.66%	Beta	0.34	Target Price	19.64
Payout	-	Debt/Eq	0.08	Sales Q/Q	-	SMA50	67.43%	Rel Volume	1.13	Prev Close	12.45
Employees	205	LT Debt/Eq	0.07	Earnings	May 06 BMO	SMA200	58.58%	Avg Volume	2.76M	Price	12.69
IPO	Mar 29, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	-7.17% -	Trades		Volume	1,541,796	Change	1.94%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$17
Dec-11-24	Downgrade	Needham	Buy → Hold
Feb-26-24	Downgrade	Robert W. Baird	Outperform → Neutral	$14 → $8
Feb-08-24	Initiated	Citigroup	Buy	$11
Dec-11-23	Downgrade	Wedbush	Outperform → Neutral	$5
Dec-08-23	Initiated	JP Morgan	Overweight	$18
Apr-28-23	Initiated	Robert W. Baird	Outperform	$20
Mar-27-23	Resumed	H.C. Wainwright	Buy	$28
Dec-14-22	Initiated	Needham	Buy	$24
Jun-28-22	Initiated	Guggenheim	Buy	$15
Oct-11-21	Initiated	H.C. Wainwright	Buy	$25
Jun-09-21	Resumed	Jefferies	Buy	$20
Dec-23-20	Initiated	Piper Sandler	Overweight	$22
Oct-14-20	Initiated	Ladenburg Thalmann	Buy	$4

Show Previous Ratings

Jul-18-25 06:19PM	Rocket, TaskUS, Appian, and More Stocks See Action From Activist Investors (Barrons.com)
Jul-16-25 12:23PM	Jefferies Raises Cogent Biosciences (COGT) PT, Keeps Buy Rating (Insider Monkey)
Jul-10-25 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Shares of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares (GlobeNewswire)
Jul-08-25 09:36PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire) +6.34%
04:26PM	Cogent Biosciences Announces Proposed $150 Million Public Offering of Common Stock (GlobeNewswire)
10:54AM	Loading…
10:54AM	COGT Stock Soars on Phase III Systemic Mastocytosis Study Success (Zacks)
Jul-07-25 07:06AM	Cogent Biosciences Announces Positive Top-line Results Achieving Statistical Significance Across All Primary and Key Secondary Endpoints from the SUMMIT Trial of Bezuclastinib in Patients with Non-Advanced Systemic Mastocytosis (GlobeNewswire) +23.35%
Jun-11-25 08:00AM	Cogent Biosciences Secures up to $400 Million in Non-Dilutive Financing (GlobeNewswire)
May-29-25 08:00AM	Cogent Biosciences Announces Participation in the Jefferies Global Healthcare Conference (GlobeNewswire) +12.91%
May-13-25 09:55AM	Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade (Zacks)
08:50AM	Why Cogent Biosciences (COGT) Is One of the Best Low Priced Biotech Stocks to Buy Now (Insider Monkey)
May-06-25 08:00AM	Cogent Biosciences Reports First Quarter 2025 Financial Results (GlobeNewswire) -15.62%
May-05-25 07:57AM	Is Cogent Biosciences, Inc. (COGT) the Best Small Cap Stock to Buy with the Biggest Upside Potential? (Insider Monkey) -5.11%
Apr-25-25 08:08AM	Cogent Biosciences Presents Four Posters at the American Association for Cancer Research Annual Meeting 2025 and Announces Two New Leaders (GlobeNewswire)
Apr-20-25 06:16AM	Cogent Biosciences (COGT): Among the Most Promising Penny Stocks According to Analysts (Insider Monkey)
10:03AM	Loading…
Apr-16-25 10:03AM	Is Cogent Biosciences Inc. (NASDAQ:COGT) the Best Biotech Penny Stock to Buy According to Hedge Funds? (Insider Monkey) -12.32%
Apr-09-25 04:28PM	Cogent: Several 2025 Readouts On Deck With Bezuclastinib Advancement (Seeking Alpha) +7.73% -9.87%
Mar-25-25 04:31PM	Cogent Biosciences Announces Multiple Poster Presentations at 2025 American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire) -6.76% -6.23%
Mar-20-25 08:32AM	Is Cogent Biosciences (COGT) Stock a Solid Choice Right Now? (Zacks)
Mar-07-25 08:00AM	Cogent Biosciences Announces Participation in the Leerink Healthcare Conference (GlobeNewswire) -5.40%
Feb-27-25 08:00AM	Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire)
Feb-25-25 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results (GlobeNewswire) -6.30%
Feb-10-25 09:15AM	Cogent Biosciences Announces Bezuclastinib Poster in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2025 AAAAI Annual Meeting (GlobeNewswire)
Jan-30-25 08:00AM	Cogent Biosciences to Participate in the Guggenheim Biotech Conference (GlobeNewswire)
Jan-13-25 08:00AM	Cogent Biosciences Announces Planned 2025 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire)
Jan-08-25 08:00AM	Cogent Biosciences Announces Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-09-24 07:00AM	Cogent Biosciences Announces Updated Clinical Results from SUMMIT, Showcasing Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients (GlobeNewswire) +8.77%
Dec-08-24 12:00PM	Cogent Biosciences Announces Positive Updated Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Nov-05-24 09:00AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 66th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire) -15.84%
Oct-23-24 07:00AM	Cogent Biosciences Announces Pipeline Expansion into KRAS and Poster Presentations at the 2024 EORTC-NCI-AACR International Symposium on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
08:03AM	Loading…
Oct-09-24 08:03AM	Analysts Rate Cogent Biosciences, Inc. (COGT) as Moderate Buy with $15 Target (Insider Monkey)
Sep-03-24 08:00AM	Cogent Biosciences Announces Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) Has Completed Enrollment and Advanced Past Interim Futility Analysis (GlobeNewswire)
Sep-02-24 05:22PM	10 Best Small-Cap Healthcare Stocks To Buy Now (Insider Monkey)
Aug-06-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2024 Financial Results (GlobeNewswire)
Jun-28-24 09:18AM	Cogent (COGT) Up on SUMMIT Study Update Post Positive FDA Meeting (Zacks)
Jun-27-24 08:00AM	Cogent Biosciences Announces Positive FDA Meeting and Alignment on MS2D2, a Novel Patient Reported Outcome Measure for the SUMMIT Trial (GlobeNewswire)
Jun-14-24 07:30AM	Cogent Biosciences Announces Additional Clinical Data from Part 1 of its Ongoing SUMMIT Trial Evaluating Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire) -6.18%
May-23-24 05:05PM	Cogent Biosciences Appoints Cole Pinnow as Chief Commercial Officer (GlobeNewswire) -6.72% +9.75%
05:01PM	Cogent Biosciences Announces Positive Updated Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) at ASCO Annual Meeting (GlobeNewswire)
May-07-24 01:52PM	COGT Stock Earnings: Cogent Biosciences Misses EPS for Q1 2024 (InvestorPlace)
08:00AM	Cogent Biosciences Reports First Quarter 2024 Financial Results (GlobeNewswire)
Apr-09-24 09:00AM	Cogent Biosciences Presents Data Highlighting Potential Best-in-Class Potency and Selectivity of Novel, EGFR Sparing, CNS-Penetrant ErbB2 Inhibitor (GlobeNewswire) +7.21%
Mar-13-24 07:06AM	5 Best Biotech Stocks To Buy Under $20 (Insider Monkey)
Feb-28-24 04:32AM	COGT Reports Full Year 2023 Financial Results and Business Highlights (GuruFocus.com)
Feb-26-24 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Feb-22-24 02:30PM	Cogent Biosciences Announces Positive Part 1b Data from SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (GlobeNewswire)
Feb-14-24 07:00AM	Cogent Biosciences Announces Oversubscribed $225 Million Private Placement (GlobeNewswire) +59.34%
Feb-05-24 09:00AM	Cogent Biosciences to Present SUMMIT Part 1b Data with Bezuclastinib in NonAdvanced Systemic Mastocytosis (NonAdvSM) at the 2024 AAAAI Annual Meeting (GlobeNewswire) +18.75%
Jan-09-24 08:00AM	Cogent Biosciences Announces Planned 2024 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Therapeutics (GlobeNewswire) -7.73%
Jan-02-24 08:00AM	Cogent Biosciences Announces Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +6.12%
Dec-11-23 07:55AM	Cogent Biosciences Announces Positive Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) -53.01%
Dec-09-23 01:30PM	Cogent Biosciences Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis (NonAdvSM) (GlobeNewswire)
Dec-07-23 09:00AM	Cogent Biosciences Presents New Preclinical Data Highlighting Potential Best-in-Class Potency and Selectivity of ErbB2 and PI3K inhibitor programs at the San Antonio Breast Cancer Symposium (GlobeNewswire)
Dec-04-23 08:00AM	Cogent Biosciences to Host Investor Webcast on December 11, 2023 at 8:00 AM ET to Review Clinical Data Being Presented at American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
Nov-29-23 08:00AM	Cogent Biosciences Announces Poster Presentations at Upcoming San Antonio Breast Cancer Symposium (GlobeNewswire) +5.67%
Nov-02-23 09:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2023 Financial Results (GlobeNewswire)
Oct-14-23 12:30PM	Cogent Biosciences Presents Preclinical Data Highlighting Precision Oncology Pipeline at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics (GlobeNewswire)
Aug-13-23 08:51AM	After losing 15% in the past year, Cogent Biosciences, Inc. (NASDAQ:COGT) institutional owners must be relieved by the recent gain (Simply Wall St.)
Aug-08-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2023 Financial Results (GlobeNewswire) +7.62%
Jul-10-23 07:35PM	Analysts Say These 2 Stocks Are Their Top Picks for the Rest of 2023 (TipRanks)
Jun-09-23 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock (GlobeNewswire)
Jun-07-23 09:00AM	Cogent Biosciences Announces Participation in the Jefferies Healthcare Conference (GlobeNewswire) -10.21%
Jun-06-23 08:25PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock (GlobeNewswire)
04:05PM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-03-23 02:15PM	Cogent Biosciences Announces Positive Lead-In Data from Ongoing Phase 3 PEAK Trial Evaluating Bezuclastinib in Combination with Sunitinib in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-23-23 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Lead-In Data Being Presented at ASCO from the Ongoing Phase 3 PEAK Trial in Patients with Gastrointestinal Stromal Tumors (GIST) (GlobeNewswire)
May-09-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2023 Financial Results (GlobeNewswire)
Apr-17-23 09:00AM	Cogent Biosciences Presents Preclinical Data at AACR Annual Meeting Highlighting Precision Therapy Pipeline and Announces Initiation of Part 2 of the Registration-Enabling APEX Trial with Bezuclastinib in Advanced Systemic Mastocytosis (GlobeNewswire) +6.62%
Apr-12-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.74%
Mar-14-23 08:00AM	Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire) +7.54%
Feb-01-23 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire)
Jan-11-23 11:03AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.)
Jan-09-23 08:00AM	Cogent Biosciences Announces Planned 2023 Milestones for Bezuclastinib and Emerging Portfolio of Selective and Potent Targeted Cancer Therapeutics (GlobeNewswire)
Jan-05-23 08:00AM	Cogent Biosciences Announces Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-11-22 05:30PM	Cogent Biosciences Announces Positive Updated Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire)
Dec-05-22 08:00AM	Cogent Biosciences to Host Investor Webcast to Discuss Updated Clinical Data at ASH from the Ongoing Phase 2 APEX Trial of Bezuclastinib in Patients with Advanced Systemic Mastocytosis (GlobeNewswire)
Nov-28-22 04:15PM	Cogent Biosciences Appoints Rachael Easton, MD, Ph.D., VP, Head of Clinical Development (GlobeNewswire) +6.14%
Nov-14-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2022 Financial Results (GlobeNewswire)
Nov-09-22 08:00AM	Cogent Biosciences Announces Participation at Upcoming Investor Conferences (GlobeNewswire) -5.63%
Nov-03-22 09:05AM	Cogent Biosciences Announces Bezuclastinib Presentations at the 64th Annual American Society of Hematology (ASH) Meeting (GlobeNewswire)
Oct-26-22 07:00AM	Cogent Biosciences to Showcase Precision Therapy Pipeline at the EORTC-NCI-AACR Annual Meeting (GlobeNewswire)
Aug-14-22 12:21PM	2 Monster Growth Stocks That Could Reach New Highs (TipRanks)
Aug-09-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and Second Quarter 2022 Financial Results (GlobeNewswire)
Aug-04-22 11:22AM	Companies Like Cogent Biosciences (NASDAQ:COGT) Are In A Position To Invest In Growth (Simply Wall St.) +12.58%
Jun-20-22 11:09AM	Is Cogent Biosciences, Inc. (NASDAQ:COGT) Popular Amongst Institutions? (Simply Wall St.)
Jun-16-22 04:01PM	Cogent Biosciences Announces Closing of Upsized Public Offering of Common Stock and Pre-funded Warrants and Full Exercise of Underwriters Option to Purchase Additional Shares (GlobeNewswire) -6.47% +17.82%
Jun-13-22 09:48PM	Cogent Biosciences Announces Pricing of Upsized Public Offering of Shares of Common Stock and Pre-funded Warrants (GlobeNewswire) +11.05%
06:00AM	Cogent Biosciences Announces Proposed Public Offering of Common Stock (GlobeNewswire)
Jun-10-22 07:00AM	Cogent Biosciences Announces Positive Initial Clinical Data from Ongoing Phase 2 APEX Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis (AdvSM) (GlobeNewswire) +58.67%
Jun-06-22 10:15AM	Cogent Biosciences to Host Investor Webcast on June 10, 2022 at 8:00am ET (GlobeNewswire)
Jun-02-22 08:00AM	Cogent Biosciences Announces Annual Meeting of Stockholders (GlobeNewswire)
May-12-22 10:00AM	Cogent Biosciences Announces Presentation at European Hematology Association (EHA) Annual Congress (GlobeNewswire) -7.11%
May-10-22 07:00AM	Cogent Biosciences Reports Recent Business Highlights and First Quarter 2022 Financial Results (GlobeNewswire) -8.29%
May-06-22 08:00AM	Cogent Biosciences to Participate in the LifeSci Partners Immunology and Inflammation Symposium (GlobeNewswire)
Apr-11-22 07:00AM	Cogent Biosciences Presents Nonclinical Data at AACR Annual Meeting and Provides Updates on Portfolio Expansion at R&D Investor Event (GlobeNewswire)
Mar-29-22 07:00AM	Cogent Biosciences to Host Virtual R&D Investor Event (GlobeNewswire) +5.79%
Mar-15-22 07:00AM	Cogent Biosciences Provides Corporate Updates, Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-08-22 05:10PM	Cogent Biosciences Announces Upcoming Presentations at AACR Annual Meeting 2022 (GlobeNewswire)
Feb-01-22 05:29AM	Cogent Biosciences (NASDAQ:COGT) Is In A Good Position To Deliver On Growth Plans (Simply Wall St.)
Jan-05-22 07:00AM	Cogent Biosciences Provides 2022 Corporate Guidance (PR Newswire)

Cogent Biosciences, Inc. is a biotechnology company, which engages in the development of precision therapies for genetically defined diseases. It focuses on CGT9486, a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. The company was founded by Charles Wilson and Dario Campana in March 2014 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Jul 10 '25	Buy	9.00	2,777,777	24,999,993	9,003,418	Jul 14 04:30 PM
Pinnow Cole	Chief Commercial Officer	Jan 14 '25	Buy	7.60	43,750	332,412	45,848	Jan 15 07:00 AM

Dollar change +1.19
Percentage change 7.04	%

VRDN Viridian Therapeutics Inc daily Stock Chart

Peers: REGN VRTX EXEL SRPT BMRN ALNY RARE IONS ADAP PBYI

| Held by: VTI IWM XBI VXF IWO SCHA VTWO IWC VHT IWN

Index	RUT	P/E	-	EPS (ttm)	-4.05	Insider Own	9.78%	Shs Outstand	81.59M	Perf Week	8.13%
Market Cap	1.48B	Forward P/E	-	EPS next Y	-3.80	Insider Trans	0.00%	Shs Float	73.61M	Perf Month	23.41%
Enterprise Value	1.06B	PEG	-	EPS next Q	-1.00	Inst Own	103.57%	Short Float	14.64%	Perf Quarter	31.94%
Income	-293.24M	P/S	4937.48	EPS this Y	-7.33%	Inst Trans	0.35%	Short Ratio	14.68	Perf Half Y	-1.39%
Sales	0.30M	P/B	3.56	EPS next Y	5.99%	ROA	-45.42%	Short Interest	10.78M	Perf YTD	-5.30%
Book/sh	5.09	P/C	2.33	EPS next 5Y	18.32%	ROE	-49.41%	52W High	27.20 -33.26%	Perf Year	25.46%
Cash/sh	7.80	P/FCF	-	EPS past 3/5Y	22.74% 31.28%	ROIC	-46.77%	52W Low	9.90 83.38%	Perf 3Y	33.49%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-53.29% -41.64%	Gross Margin	-334.44%	Volatility	4.04% 5.07%	Perf 5Y	24.76%
Dividend TTM	-	EV/Sales	3522.02	EPS Y/Y TTM	10.13%	Oper. Margin	-111591.06%	ATR (14)	0.83	Perf 10Y	-95.44%
Dividend Ex-Date	-	Quick Ratio	19.49	Sales Y/Y TTM	4.86%	Profit Margin	-97100.00%	RSI (14)	69.83	Recom	1.25
Dividend Gr. 3/5Y	- -	Current Ratio	19.49	EPS Q/Q	-34.47%	SMA20	12.85%	Beta	0.47	Target Price	38.40
Payout	-	Debt/Eq	0.04	Sales Q/Q	0.00%	SMA50	21.39%	Rel Volume	0.55	Prev Close	16.96
Employees	143	LT Debt/Eq	0.04	Earnings	May 06 BMO	SMA200	4.60%	Avg Volume	734.32K	Price	18.15
IPO	Jun 18, 2014	Option/Short	Yes / Yes	EPS/Sales Surpr.	10.01% 41.45%	Trades		Volume	199,784	Change	7.04%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-19-24	Downgrade	Wells Fargo	Overweight → Equal Weight	$37 → $27
Nov-25-24	Initiated	TD Cowen	Buy
Sep-11-24	Reiterated	Needham	Buy	$30 → $38
Jun-11-24	Initiated	Wolfe Research	Outperform	$29
Jun-06-24	Initiated	Goldman	Buy	$23
May-09-24	Downgrade	Ladenburg Thalmann	Buy → Neutral
May-09-24	Downgrade	B. Riley Securities	Buy → Neutral	$25 → $20
Jun-14-23	Resumed	Credit Suisse	Outperform	$51
Jun-14-23	Initiated	BTIG Research	Buy	$46
May-30-23	Initiated	RBC Capital Mkts	Outperform	$44
Apr-17-23	Initiated	Wells Fargo	Overweight	$46
Mar-30-23	Initiated	Stifel	Buy	$49
Dec-19-22	Initiated	Needham	Buy	$45
Dec-19-22	Initiated	Cowen	Outperform	$45
Dec-16-22	Initiated	Credit Suisse	Outperform	$51
Dec-01-22	Initiated	H.C. Wainwright	Buy	$35
Jun-23-22	Initiated	B. Riley Securities	Buy	$25
Nov-18-21	Initiated	SVB Leerink	Outperform	$32
Oct-12-21	Initiated	Evercore ISI	Outperform	$40
Jan-25-21	Initiated	Ladenburg Thalmann	Buy	$40

Show Previous Ratings

Jul-15-25 08:58AM	Viridian Therapeutics' Veligrotug Shows Durable Proptosis Response in Phase 3 TED Trial (Insider Monkey) -5.13%
Jul-03-25 07:00AM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-05-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-30-25 07:00AM	Viridian Therapeutics to Participate in Upcoming June Investor Conferences (Business Wire)
May-20-25 07:00AM	Viridian Therapeutics Announces Positive Long-Term Durability Data from the Veligrotug Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (TED) (Business Wire) +7.80%
04:15PM	Loading…
May-07-25 04:15PM	Viridian Therapeutics Receives FDA Breakthrough Therapy Designation for Veligrotug for the Treatment of Thyroid Eye Disease (TED) (Business Wire)
May-06-25 08:10AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Lags Revenue Estimates (Zacks) -8.31%
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2025 Financial Results (Business Wire)
May-02-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Apr-15-25 08:09AM	Argenx (ARGX) Moves 4.4% Higher: Will This Strength Last? (Zacks)
Apr-07-25 07:00AM	Viridian Therapeutics Appoints Jeff Ajer to its Board of Directors (Business Wire)
Mar-19-25 05:07PM	Immunovant: TED Data Sets Stage For Batoclimab Regulatory Filings Going Forward (SeekingAlpha)
Mar-10-25 07:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Feb-27-25 07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2024 Financial Results (Business Wire)
Feb-06-25 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
07:00AM	Loading…
Jan-08-25 07:00AM	Viridian Therapeutics Highlights 2025 Corporate Priorities Following Positive Phase 3 Topline Data in Thyroid Eye Disease (Business Wire) -8.42%
Dec-17-24 07:40AM	Viridian Therapeutics announces THRIVE-2 trial met primary, secondary endpoints (TipRanks)
Dec-16-24 04:09PM	Viridian Stock Flashes A Bullish Sign In Its Eye-Disease Battle With Amgen (Investor's Business Daily) +20.67%
09:28AM	Viridian Therapeutics Skyrockets After Besting Amgen In Thyroid Eye Disease (Investor's Business Daily)
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug Phase 3 THRIVE-2 Clinical Trial in Patients with Chronic Thyroid Eye Disease (Business Wire)
Dec-13-24 06:00PM	Viridian Therapeutics to Webcast Veligrotug Phase 3 THRIVE-2 Topline Results on December 16, 2024 (Business Wire)
Dec-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Nov-12-24 07:00AM	Viridian Therapeutics Reports Third Quarter 2024 Financial Results and Recent Progress Including New FcRn Data (Business Wire) -12.76%
Nov-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Sep-11-24 11:25PM	Viridian Therapeutics Announces Pricing of Upsized Public Offering of Shares of Common Stock and Preferred Stock (Business Wire) +5.60%
Sep-10-24 04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire) +32.14%
07:00AM	Viridian Therapeutics Announces Positive Topline Results from Veligrotug (VRDN-001) Phase 3 THRIVE Clinical Trial in Patients with Active Thyroid Eye Disease (Business Wire)
Sep-09-24 04:01PM	Viridian Therapeutics to Webcast VRDN-001 Phase 3 THRIVE Topline Results on September 10, 2024 (Business Wire)
Sep-05-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) -9.23%
Aug-08-24 08:15AM	Viridian Therapeutics Highlights Recent Progress and Reports Second Quarter 2024 Financial Results (Business Wire)
04:01PM	Loading…
Aug-07-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jul-28-24 09:09AM	Goldman Sachs Predicts up to 165% Surge for These 2 Strong Buy Stocks (TipRanks)
Jul-25-24 08:00AM	Viridian Therapeutics Announces Completion of THRIVE-2 Enrollment for VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire)
Jul-08-24 10:38AM	3 Small-Cap Stocks With Explosive 2X Growth Potential (InvestorPlace)
Jul-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jun-27-24 09:48AM	Are Analysts Bullish on Viridian Therapeutics, Inc. (VRDN) Right Now? (Insider Monkey)
Jun-26-24 04:36PM	Top 10 Small-Cap Stocks with Highest Upside Potential (Insider Monkey)
Jun-12-24 09:11AM	Viridian (VRDN) Up 10% on Clinical Updates for Eye Disease Drug (Zacks) -5.94%
Jun-11-24 06:00AM	Viridian Therapeutics Announces Details of Subcutaneous VRDN-003 Phase 3 Clinical Program for Patients with Active and Chronic Moderate-to-Severe Thyroid Eye Disease (Business Wire) +10.15%
Jun-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-31-24 08:00AM	Viridian Therapeutics Announces Participation in Upcoming June Investor Conferences (Business Wire)
May-10-24 08:00AM	Viridian Therapeutics to Participate in Upcoming May Investor Conferences (Business Wire)
May-09-24 03:02AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com) -6.64%
May-08-24 11:54AM	VRDN Stock Earnings: Viridian Therapeutics Beats EPS, Beats Revenue for Q1 2024 (InvestorPlace)
08:36AM	Viridian Therapeutics Inc (VRDN) Q1 2024 Earnings: Narrowing Losses Amidst Clinical Advancements (GuruFocus.com)
08:25AM	Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
07:00AM	Viridian Therapeutics Highlights Recent Progress and Reports First Quarter 2024 Financial Results (Business Wire)
May-03-24 08:00AM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire) +5.62%
Apr-29-24 08:00AM	Viridian Therapeutics to Webcast First Quarter 2024 Financial Results on May 8, 2024 (Business Wire) +5.59%
Apr-04-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Mar-05-24 08:00AM	Viridian Therapeutics to Participate in the Leerink Partners Global Biopharma Conference (Business Wire)
Feb-28-24 09:55AM	How Much Upside is Left in Viridian Therapeutics, Inc. (VRDN)? Wall Street Analysts Think 97.81% (Zacks)
Feb-27-24 04:01PM	Viridian Therapeutics Highlights Recent Progress and Reports Fourth Quarter and Full Year 2023 Financial Results (Business Wire)
Feb-16-24 08:00AM	Viridian Therapeutics Appoints Jennifer Tousignant as Chief Legal Officer (Business Wire)
Feb-06-24 04:01PM	Viridian Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
Jan-17-24 10:00PM	Viridian Therapeutics Announces Pricing of Public Offering of Shares of Common Stock (Business Wire) -9.73%
04:01PM	Viridian Therapeutics Announces Proposed Underwritten Public Offering of Common Stock and Preferred Stock (Business Wire)
Jan-08-24 08:00AM	Viridian Therapeutics to Present Key 2024 Corporate Priorities at J.P. Morgan Healthcare Conference (Business Wire) +7.78%
Jan-04-24 08:00AM	Viridian Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (Business Wire)
Dec-18-23 07:00AM	Viridian Therapeutics Announces Positive Clinical Data in Healthy Volunteer Study and Selects VRDN-003 as Potential Best-in-Class Subcutaneous anti-IGF-1R Program with Extended Half-Life for Pivotal Development in Thyroid Eye Disease (Business Wire) +9.52%
Nov-21-23 08:00AM	Viridian Therapeutics to Participate in 6th Annual Evercore ISI HealthCONx Conference (Business Wire)
Nov-13-23 05:00PM	Viridian Therapeutics Inc (VRDN) Reports Q3 2023 Financial Results and Corporate Progress (GuruFocus.com) +8.79%
04:01PM	Viridian Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update (Business Wire)
Nov-08-23 08:00AM	Viridian Therapeutics to Participate in the Jefferies London Healthcare Conference (Business Wire)
Nov-03-23 08:00AM	Viridian Therapeutics Announces Encore Presentations at the 2023 Annual Meeting of the American Academy of Ophthalmology (Business Wire) +7.88%
Oct-30-23 08:30AM	Viridian Therapeutics Appoints New Chief Executive Officer, Unveils Next Generation FcRn Inhibitor Programs and Announces $185 Million Private Placement Financing (Business Wire) +5.17%
Oct-26-23 08:00AM	Viridian Therapeutics Enters Autoinjector Pen Device Customization and Supply Agreement with Ypsomed AG for Subcutaneous Drug Delivery in Thyroid Eye Disease (Business Wire) +8.57%
Sep-25-23 08:00AM	Viridian Appoints Sarah Gheuens, M.D., Ph.D., to its Board of Directors (Business Wire)
Sep-07-23 08:00AM	Viridian Therapeutics Announces Presentations at Multiple Medical Meetings in September (Business Wire)
Aug-08-23 04:01PM	Viridian Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update (Business Wire) +5.69%
Aug-04-23 04:01PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jul-10-23 04:01PM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating VRDN-001 in Patients with Chronic Thyroid Eye Disease (TED) (Business Wire) +5.06% -16.39%
Jul-06-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (Business Wire)
Jun-13-23 08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Endocrine Society (Business Wire)
Jun-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Business Wire)
May-09-23 04:01PM	Viridian Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update (GlobeNewswire)
May-08-23 08:00AM	Viridian Therapeutics Announces Partnership with Drug Delivery Innovator Enable Injections (GlobeNewswire)
May-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-02-23 08:00AM	Viridian Therapeutics to Webcast First Quarter 2023 Financial Results and Corporate Update on May 9, 2023 (GlobeNewswire)
Apr-20-23 01:41PM	UPDATE Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
08:00AM	Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology (GlobeNewswire)
Apr-16-23 09:50AM	TipRanks Perfect 10 List: 2 Top-Rated Stocks Potentially Undervalued by ~90% (TipRanks)
Apr-13-23 06:52AM	Daily Vickers Top Buyers & Sellers for 04/13/2023 (Argus Research)
Apr-12-23 08:00AM	Viridian Therapeutics Appoints Tony Casciano as Chief Commercial Officer (GlobeNewswire)
Apr-04-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-08-23 07:00AM	Viridian Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates (GlobeNewswire) -10.48%
Mar-07-23 08:00AM	Viridian Therapeutics Announces Presentations at the 49th Annual Meeting of the North American Neuro-Ophthalmology Society (GlobeNewswire)
Mar-03-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Mar-01-23 08:00AM	Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023 (GlobeNewswire)
Feb-28-23 08:00AM	Viridian Therapeutics to Participate in Cowens 43rd Annual Health Care Conference (GlobeNewswire)
Feb-07-23 08:00AM	Viridian Therapeutics to Participate in the SVB Securities Virtual Global Biopharma Conference (GlobeNewswire)
Feb-06-23 07:00AM	Viridian Appoints Scott Myers as President and Chief Executive Officer (GlobeNewswire)
Feb-02-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) (GlobeNewswire)
Jan-08-23 08:00AM	Viridian Announces Positive Data from Ongoing Phase 1/2 Trial Evaluating Low Dose VRDN-001 in Patients with Thyroid Eye Disease (TED) (GlobeNewswire)
Jan-05-23 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-03-23 08:00AM	Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Dec-21-22 07:00AM	Viridian Therapeutics Announces First Patient Enrolled in the THRIVE Phase 3 Trial in Patients With Thyroid Eye Disease (GlobeNewswire) +7.34%
Dec-07-22 04:05PM	Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-28-22 07:00AM	Viridian Therapeutics To Participate In The Evercore ISI HealthCONx Conference (GlobeNewswire)

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Fairmount Funds Management LLC	Director	Jun 10 '25	Option Exercise	12.31	12,500	153,875	3,459,913	Jun 11 05:00 PM
Fairmount Funds Management LLC	Director	Jun 09 '25	Option Exercise	7.80	1,600	12,480	3,447,413	Jun 11 05:00 PM
Beetham Thomas W.	Chief Operating Officer	Sep 27 '24	Buy	23.41	5,000	117,050	6,000	Sep 30 07:12 PM
Mahoney Stephen F.	President and CEO	Sep 27 '24	Buy	23.33	21,400	499,262	21,400	Sep 30 07:10 PM
Fairmount Funds Management LLC	Director	Sep 13 '24	Buy	18.75	1,600,000	30,000,000	3,445,813	Sep 17 09:00 PM

Open in Screener

ZBIO

Zenas Biopharma Inc

Jul 23 • 12:31PM ET

15.00

Dollar change +0.69
Percentage change 4.82	%

Healthcare • Biotechnology • USA • NASD

ZBIO Zenas Biopharma Inc daily Stock Chart

Held by: VTI IWM VXF IWN SCHA VTWO IWC FESM SBIO RSSL

Index	RUT	P/E	-	EPS (ttm)	-3.98	Insider Own	75.62%	Shs Outstand	41.82M	Perf Week	14.77%
Market Cap	627.52M	Forward P/E	-	EPS next Y	-3.73	Insider Trans	0.11%	Shs Float	10.20M	Perf Month	58.39%
Enterprise Value	316.37M	PEG	-	EPS next Q	-1.04	Inst Own	32.99%	Short Float	50.00%	Perf Quarter	52.98%
Income	-162.76M	P/S	41.83	EPS this Y	66.58%	Inst Trans	4.31%	Short Ratio	29.75	Perf Half Y	78.57%
Sales	15.00M	P/B	2.21	EPS next Y	6.09%	ROA	-85.03%	Short Interest	5.10M	Perf YTD	83.15%
Book/sh	6.80	P/C	2.01	EPS next 5Y	32.39%	ROE	-115.47%	52W High	26.25 -42.86%	Perf Year	-
Cash/sh	7.47	P/FCF	-	EPS past 3/5Y	-9.85% -	ROIC	-57.18%	52W Low	5.83 157.29%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	99.15%	Volatility	6.28% 9.58%	Perf 5Y	-
Dividend TTM	-	EV/Sales	21.09	EPS Y/Y TTM	-	Oper. Margin	-1157.59%	ATR (14)	1.01	Perf 10Y	-
Dividend Ex-Date	Dec 24, 2019	Quick Ratio	6.47	Sales Y/Y TTM	-	Profit Margin	-1085.07%	RSI (14)	72.39	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	6.47	EPS Q/Q	-10.71%	SMA20	29.73%	Beta	-	Target Price	35.20
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	38.96%	Rel Volume	0.81	Prev Close	14.31
Employees	130	LT Debt/Eq	0.00	Earnings	May 15 BMO	SMA200	34.67%	Avg Volume	171.42K	Price	15.00
IPO	Sep 13, 2024	Option/Short	No / Yes	EPS/Sales Surpr.	29.43% 499.99%	Trades		Volume	68,793	Change	4.82%

Date	Action	Analyst	Rating Change	Price Target Change
Mar-20-25	Initiated	Wedbush	Outperform	$35
Feb-04-25	Initiated	Wolfe Research	Outperform	$19
Dec-16-24	Initiated	H.C. Wainwright	Buy	$30
Nov-05-24	Initiated	Rodman & Renshaw	Buy	$34
Oct-08-24	Initiated	Morgan Stanley	Overweight	$40
Oct-08-24	Initiated	Jefferies	Buy	$35
Oct-08-24	Initiated	Guggenheim	Buy	$45
Oct-08-24	Initiated	Citigroup	Buy	$27

Jun-20-25 04:15PM	Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-13-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -8.75%
Jun-02-25 04:00AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) +5.67%
May-29-25 07:05AM	Zenas BioPharma to Present at the Jefferies Global Healthcare Conference (GlobeNewswire) +8.34%
May-28-25 09:31AM	ZBIO Shareholders Have the Right to Lead the Zenas Biopharma, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - ZBIO (PR Newswire) -12.59%
05:45AM	Loading…
May-16-25 05:45AM	Investors in Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +7.49%
May-15-25 07:05AM	Zenas BioPharma Reports First Quarter 2025 Financial Results and Provides Corporate Updates (GlobeNewswire) +12.21%
May-06-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ZBIO (PR Newswire) -19.71%
May-02-25 05:45AM	Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire)
Apr-29-25 05:45AM	Zenas BioPharma, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights - ZBIO (PR Newswire) +12.56%
Apr-22-25 10:37AM	Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses (GlobeNewswire)
Apr-21-25 12:33PM	Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses (GlobeNewswire) +9.30%
Apr-17-25 04:20PM	Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.08%
Apr-07-25 03:08PM	Zenas: Differentiated B-Cell Targeting Drug With Q3 Of 2025 Catalyst (Seeking Alpha)
07:05AM	Zenas BioPharma Appoints Haley Laken, Ph.D., as Chief Scientific Officer (GlobeNewswire)
02:54PM	Loading…
Mar-20-25 02:54PM	Zenas BioPharma Gains Outperform Rating From Analyst As Key Autoimmune Trials Progress (Benzinga)
11:41AM	Zenas Bio rises as Wedbush launches with Outperform on lead asset (SeekingAlpha)
Mar-17-25 07:05AM	Zenas BioPharma Appoints Lisa von Moltke, M.D., as Head of Research and Development and Chief Medical Officer (GlobeNewswire)
Feb-05-25 07:05AM	Zenas BioPharma Announces Key 2024 Accomplishments and 2025 Business Objectives to Support the Global Development and Commercialization of Therapies for Autoimmune Diseases (GlobeNewswire)
Jan-28-25 08:00AM	Zenas BioPharma to Present at the Guggenheim SMID Cap Biotech Conference (GlobeNewswire)
Dec-17-24 06:25AM	Zenas BioPharma initiated with a Buy at H.C. Wainwright (TipRanks) +8.10%
Dec-12-24 07:35AM	Zenas BioPharma price target lowered to $35 from $40 at Morgan Stanley (TipRanks)
Nov-12-24 07:10AM	Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire)
07:05AM	Zenas BioPharma Completes Targeted Enrollment of the Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD) (GlobeNewswire)
Nov-07-24 07:05AM	Zenas BioPharma to Participate in Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-14-24 06:45AM	Opening Day: Another trio of biotech IPOs make Friday debut (TipRanks) +7.63%
Sep-19-24 04:15PM	Zenas BioPharma Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Initial Public Offering (GlobeNewswire) +8.45%
Sep-13-24 04:09PM	Biotech IPO Shares Climb in Debuts After Deals Upsized (Bloomberg)
12:19AM	Bicara Leads Trio of US Biotech IPOs Raising $703 Million (Bloomberg)
Sep-12-24 10:37PM	Zenas BioPharma Announces Pricing of Upsized Initial Public Offering (GlobeNewswire)

Zenas BioPharma, Inc. is a clinical-stage global biopharmaceutical company, which engages in the development and commercialization of transformative immunology-based therapies for patients. The company was founded by Lonnie O. Moulder Jr on November 12, 2019 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
MOULDER LEON O JR	Chief Executive Officer	Feb 18 '25	Buy	6.67	25,000	166,750	266,155	Feb 19 04:01 PM
Xiao Ting	Director	Feb 07 '25	Buy	7.76	10,000	77,600	47,000	Feb 11 04:20 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 04 '24	Buy	9.98	45,000	449,100	241,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Dec 03 '24	Buy	10.76	25,000	269,000	196,155	Dec 04 09:03 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 18 '24	Buy	15.00	7,500	112,500	168,655	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Nov 19 '24	Buy	14.57	2,500	36,425	171,155	Nov 20 05:20 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 18 '24	Buy	17.91	10,000	179,100	1,662,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 20 '24	Buy	18.45	5,000	92,270	1,672,039	Sep 20 06:34 PM
MOULDER LEON O JR	Chief Executive Officer	Sep 19 '24	Buy	17.89	5,000	89,450	1,667,039	Sep 20 06:34 PM
Enavate Sciences GP, LLC	10% Owner	Sep 16 '24	Buy	17.00	882,353	15,000,001	3,761,359	Sep 18 04:15 PM
Lu Hongbo	Director	Sep 13 '24	Buy	17.00	58,823	999,991	58,823	Sep 17 07:52 PM
ENRIGHT PATRICK G	Director	Sep 16 '24	Buy	17.00	440,000	7,480,000	774,530	Sep 16 08:57 PM
Nunn Jason Raleigh	Director	Sep 16 '24	Buy	17.00	882,352	14,999,984	1,946,564	Sep 16 08:54 PM
Fairmount Funds Management LLC	Director	Sep 16 '24	Buy	17.00	300,000	5,100,000	1,604,891	Sep 16 08:54 PM
SR ONE CAPITAL MANAGEMENT, LLC	10% Owner	Sep 16 '24	Buy	17.00	2,235,294	37,999,998	1,946,564	Sep 16 08:51 PM

Dollar change +1.26
Percentage change 6.08	%

DNTH Dianthus Therapeutics Inc daily Stock Chart

Peers: VRTX REGN BIIB GILD AMGN MRNA BMY LLY PFE ABBV

| Held by: VTI IWM XBI VXF IWN SCHA VTWO AVSC IWC LABU

Index	RUT	P/E	-	EPS (ttm)	-2.89	Insider Own	30.61%	Shs Outstand	32.13M	Perf Week	10.89%
Market Cap	707.52M	Forward P/E	-	EPS next Y	-3.57	Insider Trans	0.00%	Shs Float	22.32M	Perf Month	27.91%
Enterprise Value	445.69M	PEG	-	EPS next Q	-0.87	Inst Own	96.23%	Short Float	30.71%	Perf Quarter	0.59%
Income	-100.73M	P/S	108.52	EPS this Y	-33.00%	Inst Trans	12.41%	Short Ratio	22.83	Perf Half Y	1.57%
Sales	6.52M	P/B	2.15	EPS next Y	-5.19%	ROA	-27.56%	Short Interest	6.85M	Perf YTD	0.92%
Book/sh	10.23	P/C	2.69	EPS next 5Y	-15.32%	ROE	-28.73%	52W High	32.27 -31.83%	Perf Year	-17.17%
Cash/sh	8.18	P/FCF	-	EPS past 3/5Y	50.25% 40.14%	ROIC	-30.55%	52W Low	13.36 64.61%	Perf 3Y	-30.20%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	93.29%	Volatility	5.67% 6.98%	Perf 5Y	-81.99%
Dividend TTM	-	EV/Sales	68.36	EPS Y/Y TTM	51.03%	Oper. Margin	-1796.40%	ATR (14)	1.34	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	15.99	Sales Y/Y TTM	189.31%	Profit Margin	-1544.02%	RSI (14)	66.34	Recom	1.15
Dividend Gr. 3/5Y	- -	Current Ratio	15.99	EPS Q/Q	-53.91%	SMA20	13.02%	Beta	1.43	Target Price	51.05
Payout	-	Debt/Eq	0.00	Sales Q/Q	33.07%	SMA50	17.19%	Rel Volume	1.57	Prev Close	20.74
Employees	78	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	0.19%	Avg Volume	300.16K	Price	22.00
IPO	Jun 21, 2018	Option/Short	Yes / Yes	EPS/Sales Surpr.	3.47% 44.13%	Trades		Volume	232,445	Change	6.08%

Date	Action	Analyst	Rating Change	Price Target Change
Jul-02-25	Initiated	William Blair	Outperform
Dec-20-24	Initiated	TD Cowen	Buy
Oct-03-24	Initiated	Oppenheimer	Outperform	$48
Jul-26-24	Initiated	Robert W. Baird	Outperform	$58
Jun-27-24	Initiated	Cantor Fitzgerald	Overweight
May-16-24	Initiated	H.C. Wainwright	Buy	$40
Feb-15-24	Initiated	Stifel	Buy	$44
Dec-26-23	Initiated	Jefferies	Buy	$22
Nov-22-23	Initiated	Wedbush	Outperform	$23
Oct-30-23	Initiated	Guggenheim	Buy	$45
Sep-28-23	Initiated	Raymond James	Outperform	$24
Aug-25-22	Downgrade	Goldman	Buy → Neutral	$2
Jan-06-22	Upgrade	Goldman	Neutral → Buy	$7 → $8
Aug-20-21	Resumed	Goldman	Neutral	$7
Aug-03-21	Downgrade	JP Morgan	Overweight → Neutral	$16 → $7
Jul-22-21	Reiterated	B. Riley Securities	Buy	$21 → $19
Jun-29-21	Initiated	Cantor Fitzgerald	Overweight	$20
Jun-15-21	Initiated	BTIG Research	Buy	$20
May-18-21	Initiated	B. Riley Securities	Buy	$21
Jan-07-21	Initiated	Mizuho	Buy	$16

Show Previous Ratings

Jun-21-25 03:50PM	Stifel Reaffirms Buy on Dianthus Therapeutics, Inc. (DNTH) with 186% Upside (Insider Monkey)
May-29-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the Jefferies Global Healthcare Conference (GlobeNewswire)
May-22-25 04:10PM	Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors (GlobeNewswire)
May-12-25 05:10PM	Dianthus Therapeutics, Inc. (DNTH) Reports Q1 Loss, Tops Revenue Estimates (Zacks) -6.18%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
05:35PM	Loading…
May-07-25 05:35PM	Emergent Biosolutions (EBS) Q1 Earnings Top Estimates (Zacks)
May-05-25 07:00AM	Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September (GlobeNewswire)
Apr-29-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Events (GlobeNewswire)
Apr-23-25 02:53PM	Dianthus Therapeutics: Complement Therapy Developer With Long Road Ahead (Seeking Alpha)
Apr-03-25 10:03AM	Dianthus Therapeutics, Inc. (DNTH) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Mar-24-25 09:57AM	Alnylam (ALNY) Surges 11.8%: Is This an Indication of Further Gains? (Zacks)
Mar-11-25 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results (GlobeNewswire) -6.33%
Mar-05-25 07:00AM	Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors (GlobeNewswire) +14.60%
Feb-26-25 07:00AM	Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences (GlobeNewswire) -6.32%
Jan-30-25 07:00AM	Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences (GlobeNewswire)
07:00AM	Loading…
Jan-08-25 07:00AM	Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Nov-07-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results (GlobeNewswire)
Nov-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences (GlobeNewswire)
Oct-15-24 07:00AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting (GlobeNewswire) +8.30%
Sep-04-24 07:00AM	Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September (GlobeNewswire)
Aug-08-24 04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results (GlobeNewswire)
Jul-08-24 11:06AM	Dianthus (DNTH) Gains 18% in the Past Month: Here's Why (Zacks) +11.93%
Jun-28-24 11:30AM	Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN) (GlobeNewswire)
Jun-12-24 07:00AM	Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN) (GlobeNewswire) +5.01%
May-30-24 04:30PM	Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire) -6.59%
May-09-24 10:56PM	DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 (InvestorPlace)
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results (GlobeNewswire)
May-08-24 04:30PM	Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference (GlobeNewswire)
May-03-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +7.46% -7.29%
Apr-11-24 07:30AM	Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting (GlobeNewswire) +9.11%
04:30PM	Loading…
Apr-05-24 04:30PM	Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) -6.02%
Mar-21-24 10:54PM	DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 (InvestorPlace) +14.32%
04:01PM	Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY2023 Financial Results (GlobeNewswire)
Mar-07-24 04:30PM	Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Feb-26-24 07:00AM	Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) (GlobeNewswire)
Feb-23-24 08:00AM	Dianthus Therapeutics to Participate in the TD Cowen 44th Annual Health Care Conference (GlobeNewswire)
Jan-31-24 04:05PM	Dianthus Therapeutics to Participate at the Guggenheim 6th Annual Biotechnology Conference (GlobeNewswire) +9.05%
Jan-22-24 07:30AM	Dianthus Therapeutics Announces $230 Million Private Placement (GlobeNewswire) +37.24%
Jan-02-24 08:30AM	Dianthus Therapeutics to Webcast Presentation at the 42nd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +10.10%
Dec-14-23 07:04AM	DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 (InvestorPlace)
Nov-29-23 04:05PM	Dianthus Therapeutics Enhances Leadership Team with Appointment of Jeffrey Stavenhagen, Ph.D., as Chief Scientific Officer (GlobeNewswire)
Nov-09-23 04:05PM	Dianthus Therapeutics Highlights Recent Business Achievements and Third Quarter 2023 Financial Results (GlobeNewswire)
Sep-14-23 05:04PM	Insider Buying: Fairmount Funds Management LLC Acquires 24,254 Shares of Dianthus Therapeutics Inc (GuruFocus.com)
Aug-14-23 01:35PM	CEO of shuttered biotech Magenta Therapeutics makes leap to Flagship startup (American City Business Journals)
May-03-23 04:19PM	Magenta Sets Up Dianthus Merger After Stopping Blood Cancer Trial Due To Patient Death (Benzinga) -14.29%
07:00AM	Magenta Therapeutics and Dianthus Therapeutics Announce Merger Agreement (GlobeNewswire)
Mar-31-23 04:10PM	Magenta Therapeutics Adopts Limited Duration Stockholder Rights Plan (GlobeNewswire)
06:09AM	The Zacks Analyst Blog Highlights Blue Bird, Comfort Systems, Salesforce, Deckers Outdoor and Magenta Therapeutics (Zacks)
Mar-27-23 10:20AM	Is Magenta Therapeutics (NASDAQ:MGTA) In A Good Position To Deliver On Growth Plans? (Simply Wall St.)
Feb-09-23 01:24PM	On eve of shutdown, Cambridge biotech loses 84% of staff, including 5 execs (American City Business Journals)
10:13AM	Magenta's CEO Leaves After Patient Death Halts Trials, Shuttering Concerns Looms (Benzinga)
Feb-03-23 01:35PM	Magenta Therapeutics to shut down after patient death (American City Business Journals) +51.66%
Feb-02-23 04:05PM	Magenta Therapeutics to Explore Strategic Alternatives (GlobeNewswire)
05:58AM	The Petri Dish: Departed White House adviser returns to the Broad (American City Business Journals)
Jan-25-23 04:05PM	Magenta Therapeutics Voluntarily Pauses the MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial to Investigate Drug Safety (GlobeNewswire) +6.89% -11.09%
Dec-21-22 07:39AM	Magenta (MGTA) Down on Pipeline Update for Leukemia Drug (Zacks) -7.64%
Dec-20-22 11:20AM	Magenta Therapeutics Shares Crashes As Dose-Limiting Toxicities Observed In Lead Blood Cancer Study (Benzinga) -52.71%
09:00AM	Magenta Therapeutics Provides Update for MGTA-117 Phase 1/2 Dose Escalation Clinical Trial (GlobeNewswire)
Dec-13-22 05:56AM	Magenta Therapeutics Shares Surge After Encouraging Data From Blood Cancer Candidate At ASH Meeting (Benzinga) -7.83%
Dec-12-22 04:30PM	Magenta Therapeutics Presents Positive MGTA-117 Clinical Data at the American Society of Hematology (ASH) Annual Meeting and Provides Program Updates (GlobeNewswire)
08:00AM	Magenta Therapeutics to Host Conference Call and Webcast on Tuesday, December 13, 2022, to Review MGTA-117 Clinical Data from Ongoing Phase 1/2 Clinical Trial (GlobeNewswire)
Nov-03-22 09:01AM	Magenta Therapeutics to Present Data at the 2022 American Society of Hematology (ASH) Annual Meeting (GlobeNewswire)
09:01AM	Magenta Therapeutics Reports Third Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Nov-01-22 08:00AM	Magenta Therapeutics to Participate in the Credit Suisse 31st Annual Healthcare Conference (GlobeNewswire)
Oct-17-22 12:16PM	We Think Magenta Therapeutics (NASDAQ:MGTA) Needs To Drive Business Growth Carefully (Simply Wall St.)
Sep-23-22 09:15AM	Australian Billionaire Kerr Neilson is Selling These 15 Stocks (Insider Monkey)
Aug-17-22 08:00AM	Magenta Therapeutics Appoints Michael Vasconcelles, M.D. to the Board of Directors (GlobeNewswire)
Aug-04-22 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (GlobeNewswire)
Aug-02-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 2022 Wedbush PacGrow Healthcare Conference (GlobeNewswire)
Jul-17-22 09:04AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
May-16-22 12:29PM	Magenta Therapeutics Reveals Encouraging Interim Data From Lowest Dose Of MGTA-117 In Leukemia Trial (Benzinga)
09:35AM	After Plunging 49.1% in 4 Weeks, Here's Why the Trend Might Reverse for Magenta Therapeutics, Inc. (MGTA) (Zacks)
08:00AM	Magenta Therapeutics Reports First Quarter Financial Results, Early Clinical Observations from MGTA-117 Clinical Trial and Other Program Highlights (Business Wire)
May-10-22 11:54AM	Here's Why We're Watching Magenta Therapeutics' (NASDAQ:MGTA) Cash Burn Situation (Simply Wall St.)
Apr-14-22 04:41PM	Stem cell startup cuts staff by 14% (American City Business Journals) -7.05% -14.29%
12:15PM	Magenta Therapeutics Trims R&D, Cuts Workforce (Benzinga)
08:00AM	Magenta Therapeutics Focuses R&D and Operational Spending, Reduces Workforce and Extends Cash Runway (Business Wire)
Mar-08-22 08:00AM	Magenta Therapeutics Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Program Highlights (Business Wire) +7.06%
Mar-03-22 08:00AM	Magenta Therapeutics to Participate in Panel Discussion at the 42nd Annual Cowen Healthcare Conference (Business Wire)
Feb-07-22 09:35AM	What Kind Of Shareholders Hold The Majority In Magenta Therapeutics, Inc.'s (NASDAQ:MGTA) Shares? (Simply Wall St.)
Jan-18-22 07:00AM	Sema4 to Acquire GeneDx, Strengthening its Market-Leading AI-Driven Genomic and Clinical Data Platform (GlobeNewswire)
Jan-10-22 08:00AM	Magenta Therapeutics Highlights Recent Pipeline Progress and Milestone Expectations for 2022 (Business Wire)
Jan-05-22 08:00AM	Magenta Therapeutics to Present at the J.P. Morgan Healthcare Conference and the B. Riley Virtual Oncology Conference (Business Wire) -6.50%
Dec-14-21 09:00AM	Magenta Therapeutics Highlights Presentations of Data Related to Stem Cell Mobilization and Targeted Conditioning at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Nov-10-21 06:20AM	Big Pharma Is Going Holiday Shopping. Who's Next? (Motley Fool)
Nov-08-21 09:24AM	Companies Like Magenta Therapeutics (NASDAQ:MGTA) Are In A Position To Invest In Growth (Simply Wall St.) -6.36%
Nov-04-21 09:10AM	Magenta Therapeutics Reports Third Quarter Financial Results and Program Highlights (Business Wire)
09:09AM	Magenta Therapeutics Announces Data Presentations Related to its Mobilization and Conditioning Programs at the 2021 American Society of Hematology (ASH) Annual Meeting (Business Wire)
Oct-04-21 08:00AM	Magenta Therapeutics Appoints Jeffrey Humphrey, M.D. as Chief Medical Officer (Business Wire)
Sep-21-21 08:00AM	Magenta Therapeutics to Participate in 2021 Cantor Virtual Global Healthcare Conference (Business Wire)
Sep-15-21 08:00AM	Magenta Therapeutics Announces IND Clearance for MGTA-117 Targeted Conditioning Clinical Trial (Business Wire) +8.16%
Aug-09-21 06:20AM	How Much Of Magenta Therapeutics, Inc. (NASDAQ:MGTA) Do Institutions Own? (Simply Wall St.)
Aug-05-21 08:00AM	Magenta Therapeutics Reports Second Quarter Financial Results and Recent Program Highlights (Business Wire)
Aug-03-21 05:30PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire) -10.97%
08:00AM	Magenta Therapeutics to Participate in Upcoming Healthcare Investor Conferences in August (Business Wire)
Aug-01-21 11:50AM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (Newsfile)
Jul-30-21 09:20PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (ACCESSWIRE)
11:14AM	Were Hedge Funds Right About Magenta Therapeutics, Inc. (MGTA)? (Insider Monkey)
Jul-28-21 07:39PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (PR Newswire)
Jul-26-21 08:16PM	SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Magenta Therapeutics, Inc. - MGTA (GlobeNewswire)

Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company. It designs and delivers novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company was founded on June 17, 2015 and is headquartered in New York, NY.

COGT

Cogent Biosciences Inc

VRDN

Viridian Therapeutics Inc

ZBIO

Zenas Biopharma Inc

DNTH

Dianthus Therapeutics Inc

Upgrade your FINVIZ experience